Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Inclusion Criteria: * Pathologic or cytologic diagnosis of solid tumors or lymphoma * Metastatic disease * No curative or effective therapy exists * Measurable or nonmeasurable disease * No clinically relevant third-space fluid collections * Fluid collections must be drained before study enrollment * No leukemia * No CNS metastases Exclusion Criteria: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement) * Creatinine clearance ≥ 45 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study therapy * No active infection or other serious illness that would preclude study participation * No weight loss ≥ 10% within the past 6 weeks * No peripheral neuropathy (e.g., diabetic neuropathy) ≥ CTC grade 1 * Must be able to take concurrent vitamin B12 and folic acid PRIOR CONCURRENT THERAPY: * No more than 1 prior chemotherapy regimen for metastatic disease * More than 12 months since prior adjuvant therapy * More than 30 days since prior drug that has not received regulatory approval * More than 30 days since prior radiation therapy and recovered (alopecia allowed) * Prior standard postoperative adjuvant radiation therapy for rectal cancer allowed * No prior radiation therapy to ≥ 25% of bone marrow * No prior oxaliplatin or pemetrexed disodium * No NSAIDs or acetylsalicylic acid 2 days before (5 days for long-acting agents \[e.g., piroxicam\]), during, and for 2 days after each dose of pemetrexed disodium * No concurrent nonpalliative radiation therapy or surgery for cancer * No concurrent hormonal cancer therapy (except medroxyprogesterone) * No other concurrent experimental medications (except thymidine) * No other concurrent chemotherapy or immunotherapy * No other concurrent anticancer therapy * Concurrent palliative radiation therapy allowed for small areas of painful metastasis that cannot be managed adequately by systemic or local analgesics